logo
logo

Exo Therapeutics Raises $78 Million Series B Financing

Exo Therapeutics Raises $78 Million Series B Financing

10/05/21, 10:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$78 million
Round Type
series b
Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, today announced the completion of a $78 million Series B financing. New investor, Nextech Invest, led the oversubscribed round with participation from BVF Partners, L.P., Samsara Biocapital, Morningside and Casdin Capital. Existing investors Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital also participated in the financing. Proceeds will be used to advance therapeutic candidates in oncology and inflammation derived from the company’s proprietary ExoSightTM platform towards proof-of-concept and into the clinic

Company Info

Company
Exo Therapeutics
Location
cambridge, maryland, united states
Additional Info
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit www.exo-therapeutics.com/.